

Wakefield District Women's Health Leads

Case Study

Breast Cancer and Fezolinetant



Patient:

A patient with a past medical history of breast cancer had read about Fezolinetant and has requested a prescription for hot flushes.

Background

- Fezolinetant was licensed by the MHRA in December 2023 for treating vasomotor symptoms.
- As a neurokinin 3 receptor antagonist, it works by influencing brain neurotransmitters that regulate vasomotor symptoms through the hypothalamic-pituitary-ovarian axis.
- It is awaiting NICE appraisal, expected in May 2025, and is not yet classified by the West Yorkshire Area Prescribing Committee, making it unavailable for NHS prescription at this time.
- It is currently a RED drug pending NICE appraisal.

NICE

National Institute
for Health and
Care Excellence



Outcome

- As we are unable as yet to prescribe the drug the patient requested, we discussed other options including SSRI's and clonidine.
- But also discussed the role of CBT - including Turning Points CBT for menopause support - patients can self refer
<https://talking.turning-point.co.uk/>

**TURNING
POINT**

inspired by possibility

